| Name | Title | Contact Details |
|---|
Intuitive Surgical, Inc. (NASDAQ: ISRG) is the global technology leader in minimally invasive robotic-assisted surgery. The Company`s da Vinci® Surgical System enables surgeons to operate minimally invasively through a few small incisions or the belly button from a nearby ergonomic console. The da Vinci System features a magnified 3D HD vision system and tiny wristed instruments that bend and rotate far greater than the human hand. As a result of this technology, da Vinci enables surgeons to operate with enhanced vision, precision and control.
Acumed Medical is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
KOTYS is a Powell, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Engage with your audience through hand sanitizing billboards. Terraboost Media has established a network of 52,000 boards throughout the top 130 DMAs in supermarkets, drug stores, shopping malls and airports reaching an audience of over 1.4 billion per month. Brands can literally engage with their audience with a dose of wellness and by selecting the vertical networks and/or zip codes, counties that matter. QR codes, brochures, business reply cards and coupons provide advertisers with means of tracking. Join the over 180 satisfied repeat brands who continue to leverage this engaging media platform of which Arbitron research confirms 63% ad recall and 93% positive brand opinion, along with a 30% lift in purchase intent.
BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.